PKNOX2

Across TCGA pan-cancer cohorts, PKNOX2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PKNOX2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PKNOX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PKNOX2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

LSCC, GBM, and LUAD are the cancer types where PKNOX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	III,IV	0.221	0.702	.008	20	view →
GBM	OS	Quartile	All	0.718	0.299	.004	18	view →
LUAD	OS	Quartile	II,III,IV	0.801	0.381	.009	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PKNOX2–LSCC (DFS)

Open the LSCC breakdown →